EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document E2018G0607(03)

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2016

OJ C 195, 7.6.2018, p. 26–43 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

7.6.2018   

EN

Official Journal of the European Union

C 195/26


Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2016

(2018/C 195/11)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July-31 December 2016, at their meeting on 17 March 2017:

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

Annex V

List of suspended marketing authorisations


ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July-31 December 2016:

EU Number

Product

Country

Date of authorisation

EU/1/12/793

Xalkori (Switch to non-conditional)

Liechtenstein

31.12.2016

EU/1/13/848

Erivedge (Switch to non-conditional)

Liechtenstein

31.12.2016

EU/1/15/1066

Ongentys

Iceland

13.7.2016

EU/1/15/1066

Ongentys

Norway

4.7.2016

EU/1/16/1091

Atazanavir Mylan

Iceland

29.8.2016

EU/1/16/1091

Atazanavir Mylan

Norway

2.9.2016

EU/1/16/1091

Atazanavir Mylan

Liechtenstein

31.8.2016

EU/1/16/1094

Ninlaro

Liechtenstein

31.12.2016

EU/1/16/1094

Ninlaro

Iceland

7.12.2016

EU/1/16/1094

Ninlaro

Norway

28.11.2016

EU/1/16/1102

Bortezomib SUN

Iceland

11.8.2016

EU/1/16/1102

Bortezomib SUN

Norway

12.8.2016

EU/1/16/1102

Bortezomib SUN

Liechtenstein

31.8.2016

EU/1/16/1103

Neparvis

Iceland

4.7.2016

EU/1/16/1105

EndolucinBeta

Iceland

25.7.2016

EU/1/16/1105

EndolucinBeta

Norway

27.7.2016

EU/1/16/1105

EndolucinBeta

Liechtenstein

31.8.2016

EU/1/16/1107

ZINBRYTA

Iceland

14.7.2016

EU/1/16/1107

Zinbryta

Norway

7.7.2016

EU/1/16/1107

Zinbryta

Liechtenstein

31.8.2016

EU/1/16/1108

Qtern

Iceland

25.7.2016

EU/1/16/1108

Qtern

Norway

4.8.2016

EU/1/16/1108

Qtern

Liechtenstein

31.8.2016

EU/1/16/1109

ZAVICEFTA

Iceland

12.7.2016

EU/1/16/1109

Zavicefta

Norway

1.7.2016

EU/1/16/1112

Odefsey

Iceland

12.7.2016

EU/1/16/1113

Enzepi

Iceland

14.7.2016

EU/1/16/1113

Enzepi

Norway

26.7.2016

EU/1/16/1113

Enzepi

Liechtenstein

31.8.2016

EU/1/16/1114

Bortezomib Hospira

Iceland

10.8.2016

EU/1/16/1114

Bortezomib Hospira

Norway

12.8.2016

EU/1/16/1114

Bortezomib Hospira

Liechtenstein

31.8.2016

EU/1/16/1115

Pemetrexed Fresenius Kabi

Iceland

16.8.2016

EU/1/16/1115

Pemetrexed Fresenius Kabi

Norway

11.8.2016

EU/1/16/1116

Epclusa

Iceland

12.7.2016

EU/1/16/1116

Epclusa

Norway

11.7.2016

EU/1/16/1116

Epclusa

Liechtenstein

31.8.2016

EU/1/16/1119

Zepatier

Iceland

11.8.2016

EU/1/16/1119

Zepatier

Norway

4.8.2016

EU/1/16/1119

Zepatier

Liechtenstein

31.8.2016

EU/1/16/1121

Zalmoxis

Iceland

7.9.2016

EU/1/16/1121

Zalmoxis

Norway

16.9.2016

EU/1/16/1121

Zalmoxis

Liechtenstein

31.10.2016

EU/1/16/1122

Aerivio Spiromax

Iceland

2.9.2016

EU/1/16/1122

Aerivio Spiromax

Norway

8.9.2016

EU/1/16/1122

Aerivio Spiromax

Liechtenstein

31.10.2016

EU/1/16/1123

Airexar Spiromax

Iceland

2.9.2016

EU/1/16/1123

Airexar Spiromax

Norway

13.9.2016

EU/1/16/1123

Airexar Spiromax

Liechtenstein

31.10.2016

EU/1/16/1124

Nordimet

Iceland

7.9.2016

EU/1/16/1124

Nordimet

Norway

30.8.2016

EU/1/16/1124

Nordimet

Liechtenstein

31.8.2016

EU/1/16/1125

Cinqaero

Iceland

7.9.2016

EU/1/16/1125

Cinqaero

Norway

31.8.2016

EU/1/16/1125

Cinqaero

Liechtenstein

31.8.2016

EU/1/16/1126

Truberzi

Iceland

7.10.2016

EU/1/16/1126

Truberzi

Norway

6.10.2016

EU/1/16/1126

Truberzi

Liechtenstein

31.10.2016

EU/1/16/1127

Tenofovir disoproxil Zentiva

Iceland

6.10.2016

EU/1/16/1127

Tenofovir disoproxil Zentiva

Liechtenstein

31.10.2016

EU/1/16/1127

Tenofovir disoproxil Zentiva

Norway

13.10.2016

EU/1/16/1128

Kisplyx

Iceland

7.9.2016

EU/1/16/1128

Kisplyx

Norway

31.8.2016

EU/1/16/1128

Kisplyx

Liechtenstein

31.8.2016

EU/1/16/1129

Tenofovir disoproxil Mylan

Iceland

16.12.2016

EU/1/16/1129

Tenofovir disoproxil Mylan

Norway

21.12.2016

EU/1/16/1130

Onivyde

Iceland

1.11.2016

EU/1/16/1130

Onivyde

Norway

4.11.2016

EU/1/16/1130

Onivyde

Liechtenstein

31.10.2016

EU/1/16/1131

Thorinane

Iceland

6.10.2016

EU/1/16/1131

Thorinane

Norway

23.9.2016

EU/1/16/1131

Thorinane

Liechtenstein

31.10.2016

EU/1/16/1132

Inhixa

Iceland

7.10.2016

EU/1/16/1132

Inhixa

Norway

5.10.2016

EU/1/16/1132

Inhixa

Liechtenstein

31.10.2016

EU/1/16/1134

Mysildecard

Iceland

6.10.2016

EU/1/16/1134

Mysildecard

Norway

29.9.2016

EU/1/16/1134

Mysildecard

Liechtenstein

31.10.2016

EU/1/16/1135

Sialanar

Iceland

7.10.2016

EU/1/16/1135

Sialanar

Norway

14.10.2016

EU/1/16/1135

Sialanar

Liechtenstein

31.10.2016

EU/1/16/1136

Cabometyx

Iceland

6.10.2016

EU/1/16/1136

CABOMETYX

Norway

20.9.2016

EU/1/16/1136

CABOMETYX

Liechtenstein

31.10.2016

EU/1/16/1137

Granpidam

Liechtenstein

31.12.2016

EU/1/16/1137

Granpidam

Iceland

6.12.2016

EU/1/16/1137

Granpidam

Norway

28.11.2016

EU/1/16/1138

Venclyxto

Iceland

8.12.2016

EU/1/16/1138

Venclyxto

Norway

13.12.2016

EU/1/16/1139

Ocaliva

Iceland

19.12.2016

EU/1/16/1139

OCALIVA

Norway

12.12.2016

EU/1/16/1141

SomaKit TOC

Iceland

15.12.2016

EU/1/16/1141

SomaKit TOC

Norway

15.12.2016

EU/1/16/1142

Parsabiv

Liechtenstein

31.12.2016

EU/1/16/1142

Parsabiv

Iceland

1.12.2016

EU/1/16/1142

Parsabiv

Norway

22.11.2016

EU/1/16/1143

Lartruvo

Liechtenstein

31.12.2016

EU/1/16/1143

Lartruvo

Iceland

1.12.2016

EU/1/16/1143

Lartruvo

Norway

18.11.2016

EU/1/16/1144

Ivabradine Zentiva

Liechtenstein

31.12.2016

EU/1/16/1144

Ivabradine Zentiva

Iceland

2.12.2016

EU/1/16/1144

Ivabradine Zentiva

Norway

28.11.2016

EU/1/16/1145

Ivabradine JensonR

Liechtenstein

31.12.2016

EU/1/16/1145

Ivabradine JensonR

Iceland

2.12.2016

EU/1/16/1145

Ivabradine JensonR

Norway

5.12.2016

EU/1/16/1146

Glyxambi

Liechtenstein

31.12.2016

EU/1/16/1146

Glyxambi

Iceland

5.12.2016

EU/1/16/1146

Glyxambi

Norway

9.12.2016

EU/1/16/1147

IBRANCE

Liechtenstein

31.12.2016

EU/1/16/1147

Ibrance

Iceland

1.12.2016

EU/1/16/1147

IBRANCE

Norway

15.11.2016

EU/1/16/1148

Emtricitabin/Tenofovir disoproxil Zentiva

Liechtenstein

31.12.2016

EU/1/16/1148

Emtricitabine/Tenofovir disoproxil Zentiva

Iceland

1.12.2016

EU/1/16/1148

Emtricitabine/Tenofovir disoproxil Zentvia

Norway

15.11.2016

EU/1/16/1151

Emtricitabine/Tenofovir disproxil Krka

Norway

21.12.2016

EU/1/16/1151

Emtricitabine/Tenofovir disoproxil Krka

Iceland

14.12.2016

EU/2/16/196

Sevocalm

Norway

11.7.2016

EU/2/16/196

Sevocalm

Liechtenstein

31.8.2016

EU/2/16/196

Sevocalm

Iceland

12.7.2016

EU/2/16/198

Sedadex

Iceland

22.8.2016

EU/2/16/198

Sedadex

Norway

30.8.2016

EU/2/16/198

Sedadex

Liechtenstein

31.8.2016

EU/2/16/199

Eravac

Iceland

10.10.2016

EU/2/16/199

ERAVAC

Norway

5.10.2016

EU/2/16/199

ERAVAC

Liechtenstein

31.10.2016

EU/2/16/200

Cepedex

Iceland

19.12.2016


ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July-31 December 2016:

EU Number

Product

Country

Date of authorisation

EU/1/06/347

Sutent

Liechtenstein

31.12.2016

EU/1/06/347

Sutent

Iceland

1.12.2016

EU/1/06/347

Sutent

Norway

15.11.2016

EU/1/06/355

ATryn

Iceland

26.7.2016

EU/1/06/355

ATryn

Norway

10.8.2016

EU/1/06/355

ATryn

Liechtenstein

31.8.2016

EU/1/06/360

Champix

Iceland

13.7.2016

EU/1/06/360

Champix

Norway

7.7.2016

EU/1/06/360

Champix

Liechtenstein

31.8.2016

EU/1/06/361

Luminity

Iceland

26.7.2016

EU/1/06/361

Luminity

Norway

6.8.2016

EU/1/06/361

Luminity

Liechtenstein

31.8.2016

EU/1/06/362

Byetta

Iceland

18.8.2016

EU/1/06/363

Sprycel

Iceland

18.8.2016

EU/1/06/363

Sprycel

Norway

12.8.2016

EU/1/06/363

Sprycel

Liechtenstein

31.8.2016

EU/1/06/364

Adrovance

Iceland

16.10.2016

EU/1/06/365

Elaprase

Iceland

16.10.2016

EU/1/06/366

Tandemact

Iceland

16.10.2016

EU/1/06/374

Lucentis

Liechtenstein

31.12.2016

EU/1/06/374

Lucentis

Iceland

2.12.2016

EU/1/06/374

Lucentis

Norway

22.11.2016

EU/1/06/379

Cystadane

Iceland

7.12.2016

EU/1/06/379

Cystadane

Norway

29.11.2016

EU/1/11/699

Fampyra

Norway

8.7.2016

EU/1/11/701

Levatiracetam Teva

Norway

4.8.2016

EU/1/11/701

Levetiracetam Teva

Iceland

26.7.2016

EU/1/11/701

Levetiracetam Teva

Liechtenstein

31.8.2016

EU/1/11/706

Levodopa/Carbidopa/Entacapone Orion

Norway

15.9.2016

EU/1/11/711

Matever

Iceland

14.7.2016

EU/1/11/711

Matever

Norway

7.7.2016

EU/1/11/711

Matever

Liechtenstein

31.8.2016

EU/1/11/712

Levetiracetam Accord

Iceland

10.8.2016

EU/1/11/712

Levetiracetam Accord

Norway

11.8.2016

EU/1/11/712

Levetiracetam Accord

Liechtenstein

31.8.2016

EU/1/11/713

Levetiracetam Actavis

Iceland

5.10.2016

EU/1/11/713

Levetiracetam Actavis

Norway

30.9.2016

EU/1/11/713

Levetiracetam Actavis

Liechtenstein

31.10.2016

EU/1/11/715

Plenadren

Iceland

15.8.2016

EU/1/11/715

Plenadren

Norway

15.8.2016

EU/1/11/715

Plenadren

Liechtenstein

31.8.2016

EU/1/11/716

Eurartesim

Iceland

15.9.2016

EU/1/11/716

Eurartesim

Norway

15.9.2016

EU/1/11/716

Eurartesim

Liechtenstein

31.10.2016

EU/1/11/717

Vyndaqel

Iceland

10.8.2016

EU/1/11/717

Vyndaqel

Norway

11.8.2016

EU/1/11/717

Vyndaqel

Liechtenstein

31.8.2016

EU/1/11/719

Telmisartan Teva Pharma

Iceland

12.7.2016

EU/1/11/722

Pioglitazone Accord

Iceland

13.12.2016

EU/1/11/722

Pioglitazone Accord

Norway

21.12.2016

EU/1/11/727

Xaluprine

Liechtenstein

31.12.2016

EU/1/11/727

Xaluprine

Iceland

6.12.2016

EU/1/11/727

Xaluprine

Norway

5.12.2016

EU/1/11/728

Pramipexole Accord

Iceland

26.7.2016

EU/1/11/728

Pramipexole Accord

Norway

4.8.2016

EU/1/11/728

Pramipexole Accord

Liechtenstein

31.8.2016

EU/1/11/731

Komboglyze

Iceland

26.7.2016

EU/1/11/731

Komboglyze

Norway

11.8.2016

EU/1/11/731

Komboglyze

Liechtenstein

31.8.2016

EU/1/11/732

Desloratadine Teva

Iceland

15.8.2016

EU/1/11/732

Desloratadine Teva

Norway

22.8.2016

EU/1/11/733

Dificlir

Iceland

29.8.2016

EU/1/11/733

Dificlir

Norway

30.8.2016

EU/1/11/733

Dificlir

Liechtenstein

31.8.2016

EU/1/11/734

Edarbi

Liechtenstein

31.12.2016

EU/1/11/734

Edarbi

Iceland

2.12.2016

EU/1/11/734

Edarbi

Norway

22.11.2016

EU/1/11/736

EDURANT

Iceland

10.8.2016

EU/1/11/736

EDURANT

Norway

11.8.2016

EU/1/11/736

EDURANT

Liechtenstein

31.8.2016

EU/1/11/737

Eviplera

Iceland

10.8.2016

EU/1/11/737

Eviplera

Norway

11.8.2016

EU/1/11/737

Eviplera

Liechtenstein

31.8.2016

EU/1/11/738

Levetiracetam Actavis Group

Iceland

15.8.2016

EU/1/11/738

Levetiracetam Actavis Group

Norway

2.9.2016

EU/1/11/738

Levetiracetam Actavis Group

Liechtenstein

31.8.2016

EU/1/11/739

Dasselta

Iceland

22.8.2016

EU/1/11/739

Dasselta

Norway

5.9.2016

EU/1/11/739

Dasselta

Liechtenstein

31.8.2016

EU/1/11/740

Ameluz

Liechtenstein

31.12.2016

EU/1/11/740

Ameluz

Iceland

7.12.2016

EU/1/11/740

Ameluz

Norway

5.12.2016

EU/1/11/741

Levetiracetam SUN

Liechtenstein

31.12.2016

EU/1/11/741

Levetiracetam Sun

Iceland

5.12.2016

EU/1/11/741

Levetiracetam SUN

Norway

23.11.2016

EU/1/11/742

Efavirenz Teva

Iceland

16.10.2016

EU/1/11/742

Efavirenz Teva

Norway

21.10.2016

EU/1/11/743

Repaglinide Accord

Iceland

14.10.2016

EU/1/11/743

Repaglinide Accord

Norway

21.10.2016

EU/1/11/745

Desloratadin Actavis

Liechtenstein

31.12.2016

EU/1/11/745

Desloratadine Actavis

Iceland

2.12.2016

EU/1/11/745

Desloratadine Actavis

Norway

25.11.2016

EU/1/11/746

Desloratadine ratiopharm

Iceland

15.8.2016

EU/1/11/746

Desloratadine ratiopharm

Norway

22.8.2016

EU/1/11/746

Desloratadine ratiopharm

Liechtenstein

31.8.2016

EU/1/11/747

Colobreathe

Iceland

10.10.2016

EU/1/11/747

Colobreathe

Norway

13.10.2016

EU/1/11/747

Colobreathe

Liechtenstein

31.10.2016

EU/1/12/750

Esmya

Liechtenstein

31.12.2016

EU/1/12/750

Esmya

Iceland

5.12.2016

EU/1/12/750

Esmya

Norway

29.11.2016

EU/1/12/751

Zelboraf

Norway

6.10.2016

EU/1/12/751

Zelboraf

Iceland

10.10.2016

EU/1/12/751

Zelboraf

Liechtenstein

31.10.2016

EU/1/12/753

Signifor

Liechtenstein

31.12.2016

EU/1/12/753

Signifor

Iceland

6.12.2016

EU/1/12/753

Signifor

Norway

24.11.2016

EU/1/12/755

Pioglitazone Actavis

Liechtenstein

31.12.2016

EU/1/12/755

Pioglitazone Actavis

Norway

9.12.2016

EU/1/12/755

Pioglitazone Actavis

Iceland

2.12.2016

EU/1/12/756

Glidipion

Norway

9.12.2016

EU/1/12/756

Glidipion

Liechtenstein

31.12.2016

EU/1/12/756

Glidipion

Iceland

2.12.2016

EU/1/12/763

Ecansya

Norway

23.12.2016

EU/1/12/793

XALKORI

Iceland

10.8.2016

EU/1/12/793

XALKORI

Norway

12.8.2016

EU/1/12/793

XALKORI

Liechtenstein

31.8.2016

EU/1/12/794

ADCETRIS

Liechtenstein

31.10.2016

EU/1/12/794

ADCETRIS

Iceland

2.11.2016

EU/1/12/794

ADCETRIS

Norway

8.11.2016

EU/1/15/1047

Blincyto

Iceland

10.10.2016

EU/1/15/1047

Blincyto

Norway

29.9.2016

EU/1/15/1047

Blincyto

Liechtenstein

31.10.2016

EU/1/16/1086

Tagrisso

Iceland

19.12.2016

EU/2/06/061

Nobilis Influenza H5N2

Iceland

13.7.2016

EU/2/11/128

Emdocam

Iceland

13.7.2016

EU/2/11/132

Nobivac Myxo-RHD

Iceland

25.8.2016

EU/2/11/132

Nobivac Myxo-RHD

Norway

30.8.2016

EU/2/11/132

Nobivac Myxo-RHD

Liechtenstein

31.10.2016

EU/2/11/133

Recocam

Iceland

17.8.2016

EU/2/11/133

Recocam

Norway

25.8.2016

EU/2/11/133

Recocam

Liechtenstein

31.8.2016

EU/2/11/134

Inflacam

Liechtenstein

31.12.2016

EU/2/11/134

Inflacam

Iceland

2.12.2016

EU/2/11/134

Inflacam

Norway

25.11.2016

EU/2/11/135

Panacur AquaSol

Liechtenstein

31.8.2016

EU/2/11/135

Panacur AquaSol

Iceland

2.9.2016

EU/2/11/135

Panacur AquaSol

Norway

5.9.2016

EU/2/11/137

Activyl Tick Plus

Norway

23.12.2016

EU/2/12/139

Zulvac 1+8 Bovis

Iceland

19.12.2016


ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July-31 December 2016:

EU Number

Product

Country

Date of authorisation

EU/1/03/267/012

Reyataz

Iceland

13.7.2016

EU/1/08/494/005

Stelara

Norway

24.11.2016

EU/1/08/494/005

Stelara

Iceland

5.12.2016

EU/1/11/714/002-003

Zytiga

Iceland

1.12.2016

EU/1/11/714/003

Zytiga

Norway

25.11.2016

EU/1/12/776/024

Fycompa

Iceland

11.10.2016

EU/1/12/776/024

Fycompa

Norway

10.10.2016

EU/1/14/939/005-006

Daklinza

Iceland

13.7.2016

EU/1/14/939/005-006

Daklinza

Norway

4.7.2016

EU/1/15/1024/002

KEYTRUDA

Iceland

24.8.2016

EU/1/15/1024/002

KEYTRUDA

Norway

26.8.2016

EU/2/97/004/050-053

Metacam

Norway

29.8.2016


ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July-31 December 2016:

EU Number

Product

Country

Date of withdrawal

EU/1/00/137

Avandia

Iceland

12.8.2016

EU/1/03/258

Avandamet

Iceland

12.8.2016

EU/1/07/385

Focetria

Iceland

12.8.2016

EU/1/08/489

Opgenra

Iceland

14.7.2016

EU/1/08/489

Opgenra

Norway

11.8.2016

EU/1/08/489

Opgenra

Liechtenstein

31.8.2016

EU/1/08/500

Fablyn

Iceland

12.8.2016

EU/1/08/506

Celvapan

Iceland

7.12.2016

EU/1/08/506

Celvapan

Liechtenstein

31.12.2016

EU/1/08/506

Celvapan

Norway

21.12.2016

EU/1/09/518

PANTECTA Control

Iceland

7.10.2016

EU/1/09/518

PANTECTA Control

Norway

20.10.2016

EU/1/09/518

PANTECTA Control

Liechtenstein

31.10.2016

EU/1/09/563

ChondroCelect

Liechtenstein

31.8.2016

EU/1/09/563

ChondroCelect

Iceland

15.8.2016

EU/1/09/563

ChondroCelect

Norway

11.8.2016

EU/1/10/657

Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Dia

Iceland

12.8.2016

EU/1/11/721

Paglitaz

Iceland

12.8.2016

EU/1/12/810

Krystexxa

Iceland

14.7.2016

EU/1/12/810

Krystexxa

Norway

6.7.2016

EU/1/12/810

Krystexxa

Liechtenstein

31.8.2016

EU/1/13/831

Capecitabine SUN

Iceland

13.7.2016

EU/1/13/831

Capecitabine SUN

Norway

6.7.2016

EU/1/13/883

Vitekta

Iceland

10.11.2016

EU/1/13/883

Vitekta

Liechtenstein

31.12.2016

EU/1/13/883

Vitekta

Norway

15.12.2016

EU/1/14/942

Clopidogrel/Acetylsalicylic acid Teva

Iceland

26.7.2016


ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July-31 December 2016:

EU Number

Product

Country

Date of suspension

EU/2/15/192

Velactis

Iceland

30.8.2016

EU/2/15/192

Velactis

Norway

29.8.2016

EU/2/15/192

Velactis

Liechtenstein

31.8.2016


Top